Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery ...

When tested in a mouse model of breast cancer, the doxorubicin-loaded nanoparticles caused fewer side effects than free ...

Oncologists vary widely in treating DLBCL with cardiomyopathy, often diverging from guidelines due to limited evidence on ...

A Peter Mac-initiated clinical trial suggests a way to dramatically improve outcomes in patients with high-risk forms of ...

Inside your body, countless processes are happening every second to keep you alive. Among them is a little-known but powerful ...

Scientists at Xi'an Jiaotong-Liverpool University (XJTLU) and Nanjing University in China have developed a new drug delivery ...

Cancer statistics are equally grim. The Kenya National Cancer Registry estimates 42,000 new cancer cases and 27,000 deaths ...

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder ...

Medicus Pharma submitted a product development plan to the FDA for an investigational new animal drug designation.

Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and ...